Jun 09, 2025
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
May 28, 2025
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
May 12, 2025
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
May 07, 2025
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
May 06, 2025
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Apr 22, 2025
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
Apr 17, 2025
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
Apr 03, 2025
Dynavax Files Preliminary Proxy Statement
Mar 06, 2025
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
Feb 25, 2025
Dynavax to Participate in Upcoming Investor Conferences
Feb 20, 2025
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
Feb 06, 2025
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
Jan 13, 2025
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Nov 11, 2024
Dynavax Announces $100 Million Accelerated Share Repurchase Program
Nov 07, 2024
Dynavax Announces $200 Million Share Repurchase Program
Aug 06, 2024
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
Jul 23, 2024
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
Jun 27, 2024
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
May 28, 2024
Dynavax to Present at Upcoming Investor Conferences
May 14, 2024
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.